SIETES :: 93213 citas

Resultados de la búsqueda por INMUNODEPRESIÓN REFINAR BÚSQUEDA

1.

Dommasch ED, Kim SC, Lee MP, Gagne JJ. Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis. JAMA Dermatol 2019:10 de mayo. [Ref.ID 103131]

2.

N.L.. Why gene-therapy drugs are so expensive. The Economist 2016:1. [Ref.ID 100562]

3.

Anónimo. Idelalisib (?Zydelig®): conclusiones de la revaluación europea de su balance beneficio-riesgo (Recomendaciones del Comité para la Evaluación de Riesgos en Farmacovigilancia Europeo-PRAC). Información para profesionales sanitarios. Categoría: Medicamentos de uso humano, seguridad. Referencia: MUH (FV), 14/2016 . Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2016:1-3. [Ref.ID 100490]

4.

Anónimo. Riesgo de reactivación del virus de la hepatitis B en pacientes tratados con imatinib, dasatinib, nilotinib, bosutinib y ponatinib (medicamentos inhibidores de la tirosina quinasa Bcr-Abl) . Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2016:8 de abril. [Ref.ID 100110]

5.

Ellis SG, Kereiakes DJ, Metger C, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang ZS, Simonton C, Stone GW, for the ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 2015;373:1905-15. [Ref.ID 99671]

6.

Boeckh M, Nichols WG, Chemaly RF, Papanicolaou GA, Wingard JR, Xie H, Syrjala KL, Flowers MED, Stevens-Ayers T, Jerome KR, Leisenring W. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med 2015;162:1-10. [Ref.ID 98728]

7.

Anónimo. Vaccines for travelers. Med Lett Drugs Ther 2014;56:115-20. [Ref.ID 98403]

8.

Anónimo. AINS: phlegmons, cellulites cervicales?. Prescrire 2014;34:516. [Ref.ID 98077]

9.

Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornháuser M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, Nowak H, Kölling K, Stobernack HP, Lischka P, Zimmermann H, Rübsamen-Schaeff H, Champlin RE, Ehninger G, for the AIC246 Study. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014;370:1781-9. [Ref.ID 97588]

10.

Anónimo. Aflibercept (Zaltrap). Prescrire 2014;34:258. [Ref.ID 97436]

11.

Thomas DL. A case for ribavirin to treat chronic hepatitis E. N Engl J Med 2014;370:1162-3. [Ref.ID 97312]

12.

Kamar N, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, Radenne S, Coilly A, Garrigue V, D'Alteroche L, Buchler M, Couzi L, Lebray P, Dharancy S, Minello A, Hourmant M, Roque-Afonso AM, Abravanel F, Pol S, Rostaing L, Mallet V. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 2014;370:1111-20. [Ref.ID 97310]

13.

Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013;309:887-95. [Ref.ID 95064]

14.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DAS, for the CARE-MS II Investigators. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39. [Ref.ID 94117]

15.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS, for the CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1818-29. [Ref.ID 94116]

16.

Sprenger T, Kappos L. Alemtuzumab for multiple sclerosis: who and when to treat?. Lancet 2012;380:1795-7. [Ref.ID 94115]

17.

Anónimo. Alemtuzumab for multiple sclerosis. Lancet 2012;380:1792. [Ref.ID 94114]

18.

Anónimo. Pneumococcal vaccine for adults. Med Lett Drugs Ther 2012;54:87-8. [Ref.ID 93956]

19.

Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012;308:43-9. [Ref.ID 93391]

20.

Shattner A. Review: biologic agents increase short-term risk for some adverse events in conditions other than HIV or AIDS. Ann Intern Med 2012;156:9. [Ref.ID 92959]